Data points from the UK’s omicron wave.

Oath Keepers militia leaders faced court last Friday.

New studies suggest saliva tests underestimated as testing method.

The BeforePay share price is at 29% below the IPO price, but what does BeforePay the company actually do?

Global COVID vaccination partly hinges on patent dispute.

Climarte is a new art gallery in Melbourne that presents as the world’s first Climate Emergency focussed art gallery.

Sorry, you’re not authorised to access this page   Hi there, you’re seeing this page because you don’t have a membership OR your account has expired.   But I have an account!   If you have just logged in to your account and you’re seeing this message, please follow the steps below: 1. Press the … Continued

Massive fee hikes and subsidy reshuffling are illogical.

Australia’s most vulnerable students punished further.

Psychedelics advocacy org to enter MDMA therapy business.

DGL Group (ASX:DGL) looks too optimistically priced at a glance, but there are a few features of the company that make me think it could well be one to watch.

Pfizer and Moderna CEOs lay out 2022 plans.

Splendour in the Grass patrons to sue NSW Police.

Questions about complications of new variant in children.

People generally prefer to believe what is comforting over the unpleasant truth, and investors can use that to profit.

‘A Lonely Girl is a Dangerous Thing’ offers another perspective to what it could be like as a young single Asian woman in Australia who defies expectation and carves her own path.

Twenty-one artists explore the possibilities of exchange and communication between humans and the natural world in ‘Birds & Language’ at Wollongong Art Gallery until 13 February 2022.

Sorry, you’re not authorised to access this page   Hi there, you’re seeing this page because you don’t have a membership OR your account has expired.   But I have an account!   If you have just logged in to your account and you’re seeing this message, please follow the steps below: 1. Press the … Continued

Supermarket shortages predicted in October letter to PM.

I think the Australian Clinical Labs (ASX: ACL) is likely to fall in the short term as the Morrison government moves to restrict PCR testing.